ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.
A number of other brokerages also recently commented on EPIX. Zacks Investment Research upgraded shares of ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Wednesday, May 22nd. HC Wainwright restated a “buy” rating on shares of ESSA Pharma in a research report on Friday, May 17th.
ESSA Pharma stock traded up $0.05 during trading hours on Tuesday, reaching $2.82. 11,180 shares of the stock were exchanged, compared to its average volume of 16,424. The stock has a market cap of $22.38 million, a P/E ratio of -1.11 and a beta of 1.85. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.06 and a current ratio of 1.06. ESSA Pharma has a 52-week low of $1.41 and a 52-week high of $4.50. The firm’s 50 day moving average is $2.21 and its 200 day moving average is $2.63.
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: What is the NASDAQ Stock Market?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.